A modified version of the ‘Atkins’ diet, with high-protein and low-carbohydrate, can effectively diminish epileptic seizures in adults, when drugs and other treatments fail, says a new study. Read the full story
Popularity: 30% [?]
Tag Archive | "Atkins diet"
- Pfizer CEO: Big Acquisitions Are an Option
- Pathway that Regulates Survival Factor Implicated in Parkinson’s
- Cancer cells ‘cheat suicide call’
- Celgene warns that anticlot drug linked to deaths
- Pfizer Looks for a Better Way to Detect Drug Risks
- NICE issues new guidelines for better access to life-extending treatments for terminally ill patients
- FDA drug approvals up in 2008
- FDA Approves Roche’s Assay that Tests Donated Blood for HIV, Hep B, and Hep C
- DNA Repair Genes Previously Linked to Cancer Are Not Statistically Significant
- The Biggest Spenders in R&D Collaborations
- FDA Panel to Weigh Fate of Heart Drug Prasugrel in February
- Equivocal Data on Plavix Flummox FDA, Doctors
- Why prostate cancer patients fail hormone deprivation therapy
- Grape extract kills cancer cells
- Possible New Target For Treating Breast Cancer
- Brain Teasers
- Metformin may enhance activity of antibody in trials
- Lilly Breaks The Mold With Buy Of ImClone
- FDA approves AstraZeneca’s SEROQUEL XR
- Pharma Goes To Market
- Abraxis and ProMetic Enter License Agreements for Up to $295 M US For Four Biopharmaceuticals
- UCB says Keppra XR epilepsy drug approved in U.S
- Cash-Poor Biotech Firms Cut Research, Seek Aid
- Horse Race Begins for New Leaders at FDA and HHS
- Novartis Changes Division Heads, Plans U.S. Job Cuts
- China Biotech in Review: Deals, Developments and Financials
- Alzheimer’s disease: approaching time zero
- Johnson & Johnson Submits New Drug Application to FDA for Carisbamate
- Therapy For Alzheimer's Disease Confirmed
- GlaxoSmithKline's Lamictal Will Continue to Dominate in the Epilepsy Drug Market
- Bayer Pays $4M Upfront to Use ImmunoGen’s Technology for a Solid Tumor Target (4)
- Vimpat Approved in Europe (3)
- Lilly to Acquire ImClone Systems in $6.5 Billion Transaction (3)
- Pharma Goes To Market (3)
- Hyperactive Neurons and Amyloid, Side by Side (2)
- Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study (2)
- Dendreon Announces Interim Data from Phase 3 PROVENGE IMPACT Trial (2)
- FDA approves AstraZeneca’s SEROQUEL XR (2)
- Protein shown to play a key role in normal development of nervous system (2)
- Brain Teasers (2)
- Astellas and Maxygen Announce Global Development Agreement (1)
- Teva and Kowa Announce Strategic Partnership (1)
- Abraxis and ProMetic Enter License Agreements for Up to $295 M US For Four Biopharmaceuticals (1)
- China Biotech in Review: Deals, Developments and Financials (1)
- Eli Lilly, Deciphera enter oncology collaboration (1)
